Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

Youn H. KimStanford Cancer Center, Stanford, CA, USA

Pierluigi PorcuDepartment of Internal Medicine, Division of Hematology/Oncology, Ohio State University, Columbus, OH, USA

Madeleine DuvicDepartment of Dermatology, University of Texas and M. D. Anderson Cancer Center, Houston, TX, USA

Amy MusiekDepartment of Dermatology, University of Pennsylvania Health System, Philadelphia, PA, USA

Alain H. RookDepartment of Dermatology, University of Pennsylvania Health System, Philadelphia, PA, USA

Lawrence A. MarkDepartment of Dermatology, Indiana University School of Medicine, Indianapolis, IN, USA

Lauren Pinter-brownDepartment of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Oday HamidEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA

Boris LinEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA

Ying BianEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA

Mark BoyeEli Lilly and Company and Subsidiaries, Indianapolis, IN, USA

Jeannette M. Dayi3 Statprobe, Cary, NC, USA

Your download is now in progress and you may close this window